ASCO GI 2023 | Mechanisms of resistance to EFGR antibodies in mCRC

Samuel Klempner, MD, Massachusetts General Hospital, Boston, MA, gives an overview of genomic alterations associated with resistance to EFGR monoclonal antibodies in patients with metastatic colorectal cancer. In a real-world study, patients with MAP kinase and TKI mutations had less favorable outcomes, and secondary mutations resulted in drugs such as panitumumab and cetuximab being less efficacious. Mutations that affected downstream signaling, as well as duration of treatment additionally increased the risk of resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ